Other: 0.9ml sodium chloride (DrugBank: Sodium chloride, Chloride)
20 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
6 | Parkinson disease | 0 |
11 | Myasthenia | 0 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
14 | Chronic inflammatory demyelinating polyneuropathy | 0 |
34 | Neurofibromatosis | 0 |
46 | Malignant rheumatoid arthritis | 0 |
50 | Dermatomyositis | 0 |
51 | Scleroderma | 0 |
53 | Sjogren syndrome | 0 |
60 | Aplastic anemia | 0 |
65 | Primary immunodeficiency | 0 |
78 | Hypopituitarism | 0 |
96 | Crohn disease | 0 |
168 | Ehlers-Danlos syndrome | 0 |
193 | Prader-Willi syndrome | 0 |
227 | Osler disease | 0 |
228 | Bronchiolitis obliterans | 0 |
271 | Ankylosing spondylitis | 1 |
288 | Autoimmune acquired coagulation factor deficiency [Autoimmune Hemorrhaphilia XIII (~Mar 2017)] | 0 |
299 | Cystic fibrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01212653 (ClinicalTrials.gov) | October 2010 | 30/9/2010 | Effect of Anti-TNF (Alpha) Treatment on Vascular Stiffness in Ankylosing Spondylitis (AS) | Effect of Anti-TNF(Alpha)Treatment on Circulating Endothelial Progenitor Cells (EPCs) and Vascular Stiffness in AS | Ankylosing Spondylitis(AS) | Drug: Simponi;Other: 0.9ml sodium chloride | Chinese University of Hong Kong | NULL | Completed | 18 Years | 75 Years | Both | 50 | Phase 4 | China |